- Home
- ACRS vs OGI Comparison
ACRS vs OGI Comparison
Compare ACRS & OGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- OGI
- Stock Information
- Founded
- ACRS 2012
- OGI 2013
- Country
- ACRS United States
- OGI Canada
- Employees
- ACRS N/A
- OGI N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- OGI Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- OGI Health Care
- Exchange
- ACRS Nasdaq
- OGI Nasdaq
- Market Cap
- ACRS 170.9M
- OGI 142.5M
- IPO Year
- ACRS 2015
- OGI N/A
- Fundamental
- Price
- ACRS $1.53
- OGI $1.01
- Analyst Decision
- ACRS Strong Buy
- OGI
- Analyst Count
- ACRS 7
- OGI 0
- Target Price
- ACRS $11.67
- OGI N/A
- AVG Volume (30 Days)
- ACRS 1.2M
- OGI 687.0K
- Earning Date
- ACRS 05-06-2025
- OGI 05-13-2025
- Dividend Yield
- ACRS N/A
- OGI N/A
- EPS Growth
- ACRS N/A
- OGI N/A
- EPS
- ACRS N/A
- OGI N/A
- Revenue
- ACRS $18,720,000.00
- OGI $115,451,336.00
- Revenue This Year
- ACRS N/A
- OGI $50.11
- Revenue Next Year
- ACRS N/A
- OGI $16.16
- P/E Ratio
- ACRS N/A
- OGI N/A
- Revenue Growth
- ACRS N/A
- OGI N/A
- 52 Week Low
- ACRS $0.95
- OGI $0.96
- 52 Week High
- ACRS $5.17
- OGI $2.37
- Technical
- Relative Strength Index (RSI)
- ACRS 28.64
- OGI 35.89
- Support Level
- ACRS $1.57
- OGI $1.04
- Resistance Level
- ACRS $1.78
- OGI $1.16
- Average True Range (ATR)
- ACRS 0.10
- OGI 0.06
- MACD
- ACRS 0.02
- OGI 0.01
- Stochastic Oscillator
- ACRS 17.74
- OGI 25.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds brands, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.